The advent of nanotechnology has introduced a variety of novel exciting possibilities into the medical and clinical field. Nanoparticles, ultra-small object sized between 100 and 1 nm, are promising diagnostic tools for various diseases among other devices, thanks to the possibility of their functionalization allowing the selective targeting of organs, tissues and cells and to facilitate their transport to primary target organs. However, brain targeting represents a still unresolved challenge due to the presence of the blood-brain barrier, a tightly packed layer of endothelial cells that prevents unwanted substances entering the central nervous system. We review a range of nanoparticles suitable for in vivo diagnostic imaging of neurodegenerative diseases and brain disorders, highlighting the possibility to potentially increase their efficiency and kinetics of brain-targeting. We also review a range of imaging techniques with an emphasis on most recently introduced molecular imaging modalities, their current status and future potential.
Introduction
Over the last few years, the rapid development of biotechnology has made possible an advance in knowledge on the molecular bases of normal or pathological functions of complex organisms. From a medical point of view this progress represented the starting point for the identification of innovative approaches for biomedical imaging in both the preclinical and clinical area. In particular, this is of considerable interest in the field of neuroimaging.
Neuroimaging includes the use of imaging techniques, such as computed tomography (CT) and magnetic resonance (MRI) to either directly or indirectly image the structure, function/pharmacology of the brain. Structural neuroimaging deals with the structure of the brain and the diagnosis of bulky intracranial diseases, such as tumor and injury; functional neuroimaging deals with the diagnosis of metabolic diseases and lesions on a small scale (such as Alzheimer's disease plaques) and also for neurological and cognitive neurosciences research (Bradley 1986) .
Technological advances made possible by complex biomedical equipment like positron emission tomography (PET) and single photon emission computed tomography (SPECT), resulted into the development of molecular imaging: non-invasive imaging measurement allowing analysis of different molecular processes at organ level including the brain (Wong and Kuhar 1988) .
Each of these imaging techniques is characterized by specific application purposes, advantages and limitations.
Structural and functional imaging of brain
CT scanning uses a computer program performing a numerical integral calculation on the measured x-ray series to estimate how much of an x-ray beam is attenuated on the basis of the density or atomic number of brain tissue elements. MRI uses magnetic fields and radio waves to produce high quality threedimensional images of brain structures without use of ionizing radiation (x-rays or radioactive tracers). CT and MRI provide images of specific structural and functional alterations of brain with high spatial resolution.
To better define neuroanatomical lesions from their adjacent tissue, CT imaging may be enhanced by the blood injection of contrast agents, that increase the contrast between blood vessels and surrounding parenchyma, contributing to improve the diagnosis of tumors and vascular malformations. Malignancies and infections that cause significant breakdown of the blood-brain barrier (BBB) (Gabathuler 2010) , allow for extravasation of contrast agents into the surrounding extracellular spaces, defining the lesion from its close tissue. The most common CT contrast agents are based on small iodinated molecules, that for the high atomic number are indeed effective in absorbing x-rays; nevertheless, their nonspecific distribution, rapid pharmacokinetics and the low sensitivity of the technique have rather limited their targeting performance. Moreover, side effects remain an important issue. MRI, in comparison with CT, has the advantage of structural and functional-imaging capabilities depending on the method used and of a better contrast among soft tissues. In addition, this technique does not require the use of ionizing radiation; thus it emerged as the imaging modality of choice for many brain disorders and has driven the need for new MRI contrasts agents able to investigate brain tissue also at the molecular level.
Gadolinium diethylene triamine pentaacetic acid (Gd-DTPA) is a low molecular weight (MW 590 Da) MRI contrast agent routinely used in clinical practice. Gd is a lanthanide metal ion with seven unpaired electrons that has been demonstrated to enhance proton relaxation because of its high magnetic moment and water coordination (Runge and Gelblum 1991) . Paramagnetic Gd chelates shorten T1 longitudinal relaxation times, producing positive contrast on T1-weighted MR images. Like iodinated intravascular CT contrast agents Gd-DTPA does not cross the BBB (Winer et al 2011) may be used for brain disorders characterized by modifications in BBB (McAteer and Choudhury 2009), such as vascular diseases, inflammatory lesions or tumors (Taheri et al 2011 , Winer et al 2011 3).
Molecular imaging of brain
In general, CT and MRI offer the advantage of imaging brain parenchyma with high resolution, particularly useful for monitoring modifications or lesions present in small regions or sub-regions of the brain (e.g. hippocampus, amygdala, substantia nigra). However, the low sensitivity of these techniques represents a limitation for the development of CT or MRI-based molecular imaging contrast agents (table 1) . And both CT and MRI are characterized by a low signal-to noise ratio.
PET measures the gamma ray emissions from biologically active probes injected into the bloodstream. The large number of radio-ligands that measure different biological functions such as hypoxia, cell proliferation, glycolysis, inflammation, fatty acid metabolism and receptors or transporter expression make possible the use of PET for clinical applications. A number of radio-ligands labelled have been developed and applied to clinical and preclinical research in oncology, cardiology, neurosciences and drug development. The advantage of PET in comparison with CT and MRI is its high sensitivity, allowing the measurement of tissue targets expressed in low amount, as in the case of receptors or transporters, after the injection of microdoses of radiopharmaceuticals detectable in tissues in the pM range (table 1) . For these reasons, PET represents a unique tool for the in vivo imaging of biological processes at molecular level. However, its application may be limited by the low resolution, that is about 5 mm for PET clinical system and 1-1.2 mm for preclinical tomography. Another potential limit of PET is represented by the short half-life of the isotopes commonly used, i.e.
11 C (20 min) and 18 F (108.9 min). Recently, the development and possibility of clinical use of long-life isotopes like 124 I and 64 Cu made PET attractive for the labelling of slow kinetics compounds. These isotopes have half-life suitable for slow kinetics studies and their chemistry is sufficiently evolved to allow the labelling of different biological compounds such as antibodies or peptides. So far the most commonly used PET tracer has been the glucose analogue (2-[ 18 F]-fluoro-2-deoxy-D-glucose, FDG). FDG is the first radiopharmaceutical developed for human use and is currently extensively utilized in clinical practice for tumor staging and follow-up. This tracer was originally developed for the brain with a few clinical indications like epilepsy and the differential diagnosis of Alzheimer's disease (AD) (Swerdlow 2007) ; in periphery it is currently under evaluation or already used for the in vivo imaging of inflammation. A number of radiopharmaceuticals have been labelled and validated to map different neurobiological properties of the brain including neurotransmission, protein deposition or inflammation. Using PET-based molecular imaging and selected radioligand like 11 C-PIB, it is now possible to evaluate in vivo the presence and distribution of amyloid deposition in patients with AD or mild cognitive impairment. Other amyloid imaging tracers like flutemetamol, florbetapir and florbetaben labelled with 18 F have been developed to be centrally produced and distributed to different PET centres. These tracers are currently undergoing formal clinical trials to establish whether they can be used to distinguish patients with AD from normal controls and those with other diseases that cause dementia (Herholz and Ebmeier 2011) . 
Hybrid techniques
PET technique is characterized by a high biological content. However, the lack of structural information makes it difficult to localize the anatomical origin of the signal. For this reason combined imaging of radionuclide-based molecular (PET or SPECT) and structural data (x-ray CT) has been firmly established and these are currently used in clinical practice as well as in preclinical research. Other multimodal systems such as PET-MRI and SPECT-MRI are under development (Slomka and Baum 2009 ).
New technologies for neuroimaging: nanoparticles
In spite of significant advances in neuroimaging, important limitations still exist and new approaches are therefore necessary.
For example, an important improvement could be the possibility of increasing the sensitivity, presently low, of those techniques that currently offer high resolution, such as CT and MRI, especially when applied to the central nervous system (CNS); a possible answer to this demand could be to enhance the delivery to the brain of contrast agents that do not cross the BBB or to increase the signal generated by the contrast agent. Another unanswered problem is how to separate the contribution of peripheral inflammation over central, in those CNS pathologies where this condition is expressed; a possible response to this issue could be to devise strategies for imaging peripheral macrophages and follow their in vivo migration. Moreover, while in the case of PET, mathematical models and the knowledge of biological and kinetic behaviour of tracers allow target imaging and quantification, in the case of CT and MRI, quantification methods are not yet available. Finally, while the signal-to-noise ratio of PET imaging depends on the more or less specific distribution of the radiopharmaceutical used and on the tissue concentration of the target, both CT and MRI are characterized by a relatively low value that may limit contrast agents' detectability: solutions for increasing this value are actively sought after.
One promising approach to solving at least part of these problems is to use engineered vehicles able to deliver contrast agents to brain and, among different devices, nanoparticle (NPs) technology is rapidly advancing (figure 1). NPs are objects sized between 100 and 1 nm (Youns et al 2011) , that work as a whole unit in terms of transport and properties.
What makes NPs attractive for medical applications is the possibility of conferring on them features such as high chemical and biological stability, feasibility of incorporating both hydrophilic and hydrophobic molecules (contrast agents or drugs) and the ability to be administered by a variety of routes (including oral, inhalational and parenteral) (Petkar et al 2011) . Moreover, NPs can be functionalized by covalent conjugation to various ligands (such as antibodies, proteins or aptamers) to target specific tissues. The large surface-area-tovolume ratio of NPs permits multiple copies of a ligand to be attached, and to dramatically increase their binding affinity via In addition, NPs may be labelled or loaded by different MRI or PET detectable elements increasing the signal and the sensitivity of the methods.
When designing NPs for clinical applications, it should be remembered that their systemic administration generates important modifications. In particular, the non-specific interaction between the shell of NPs and many classes of proteins circulating in the bloodstream leads to the adsorption of opsonins on their surface. These proteins substantially change the bare material properties determining the removal of NPs from circulation by the reticulo-endothelial system, mainly located in spleen and liver. To avoid this problem, it is advisable to maintain NPs' size below 100 nm and to coat their surface with different hydrophilic surfactants, such as polysorbates and polyethylene glycol (PEG) (Provenzale and Silva 2006) . NPs with these features, called 'stealth', are able to avoid the reticulo-endothelial system, display long circulation time and stability in blood, and may be functionalized to successfully target and cross the BBB, hence they can be utilized for neuroimaging (Gabathuler 2010 , p 2).
Nanoparticulate contrast agents

X-ray CT
Owing to the ubiquitous nature of CT in the clinical setting as well as the increasing use and development of micro-CT and hybrid systems that combine this technique with PET, MRI and SPECT, the application of NP-based imaging probes could have a significant impact on health care. The most investigated NPs in this field are gold NPs, since they have large absorption coefficients against the x-ray source used for CT imaging (Hainfeld et al 2006) and may increase the signal-to-noise ratio of the technique. To date, different types of gold NPs have been tested in a preclinical setting as contrast agents (table 2) for molecular imaging: nanospheres, nanocages, nanorods and nanoshells (Murphy et al 2008) . Gold NPs formulations as an injectable imaging agent have been utilized to study the distribution in rodent brain ex vivo (Hahn et al 2011 , Sousa et al 2010 .
MRI
To address the limitations of MRI for diagnosis of CNS diseases, several nanotechnological approaches have been devised, based on the idea of carrying a substantial payload of Gd chelates. Examples include liposomes (Krauze et al 2009) , micelles (Mao et al 2011) , dendrimers (Hahn et al 2011) , fullerenes (Fillmore et al 2011) . However, this approach has not yet achieved clinical applications.
To this end, magnetic NPs (MNPs) are of considerable interest because they may behave either as contrast agents or carriers for drug delivery (Lacroix et al 2010) . Among these, the most promising and developed NP system is represented by superparamagnetic iron oxide agents, consisting of a magnetite (Fe 3 O 4 ) and/or maghemite (Fe 2 O 3 ) crystalline core surrounded by a low molecular weight carbohydrate (usually dextran or carboxydextran) or polymer coat. Iron oxide agents shorten T2 and T2* relaxation times on T2-and T2*-weighted MRI images, creating low signal or negative contrast. They can also be detected by MRI with T1, off resonance, and steady-state free precession sequences (Sosnovik et al 2008) . Iron oxide NPs can be classified according to their core structure, such as Monocrystalline (MION; 10-30 nm diameter), or according to their size as ultra-small superparamagnetic (USPIO) (20-50 nm diameter), superparamagnetic (SPIO) (60-250 nm).
PET
The development of nanotechnologies has stimulated the research on the potential use of PET and positron emitters isotopes for the imaging of NPs. The strategy utilized is consisting in incorporating PET emitters within the components of the NP, or entrapping them within the core. Oku et al (2011) employed PET to image brain cancer using positronemitting labelled liposomes in rats. Plotkin et al (2006) used PET radioisotopes for targeting the intra-tumourally injected magnetic NPs in patients with glioblastoma. Kulkarni et al (2010) proposed radio-iodinated 5-chloro-7-iodo-8-hydroxyquinoline polymeric n-butyl-2-cyanoacrylate (CQ-PBCA) NPs as a promising delivery vehicle for in vivo SPECT ( 123 I) or PET ( 124 I) imaging agent for brain amyloid deposits.
The blood-brain barrier: a gateway to neuroimaging
As is well known by pharmacologists who are facing the difficulty, and sometimes the impossibility, to reach the brain parenchyma with drugs, a barrier exists between the BBB A peculiar difference between cerebral microvascular endothelium and the endothelia in other vascular districts is the presence in the BBB of tight junctions (TJs) between adjacent endothelial cells, a lack of fenestrations (perforations) and a lack of pinocytotic vesicles. TJs between endothelial cells of the BBB also possess an intricate complex of transmembrane proteins (junctional adhesion molecule-1 (JAM-1), occludin and claudins) with cytoplasmic accessory proteins (zonula occludens-1 and -2 (ZO-1 and 2), cingulin, AF-6 and 7H6) and hence act as physiological and pharmacological barriers. The barrier formed by endothelial cells is made even more tight by surrounding perycites and basal lamina (Correale and Villa 2009) .
It turns out from this description that the influx of solutes and other substances from the bloodstream into the brain is strictly inhibited, on the one side along the pericellular route by physical fences (TJs and adherent junctions) and, on the other side along the trans-cellular route, by metabolic and physical barriers (enzymes, diverse transport systems, membranes) (Correale and Villa 2009, p 8) .
In addition to the BBB, there exist other CNS barriers shielding the delicate brain tissue from the outer world, but which may play a role in drug transport, such as the blood cerebrospinal fluid barrier (BCSF), the blood-tumor barrier and the barrier between the systemic blood vessels of the neighbouring choroid and the retina.
BCSF is the second important barrier of the CNS next to the BBB, and is formed by the epithelial cells of the choroid plexus. BCSF controls the penetration of molecules within the interstitial fluid of the brain parenchyma by closely regulating the exchange of molecules between the blood and cerebrospinal fluid.
Overcoming the BBB: NP-mediated delivery systems
Since the transport of small molecules across the BBB has to face its impermeable membranes, nanotechnologies have been suggested as a futuristic tool to overcome this seemingly insurmountable difficulty. NPs can diffuse across the BBB only when this is leaky or damaged as a consequence of CNS diseases such as experimental autoimmune encephalomyelitis (EAE) (Oude Engberink et al 2010) , otherwise their penetration is limited (Calvo et al 2002) .
Instead, to efficiently enhance the transport of NPs to the brain, various mechanisms can be exploited to cross the BBB (figure 3), coupled with the possibility of their multifunctionalization.
Receptor-and adsorptive-mediated transcytosis are two major routes for NP delivery across the BBB (Markoutsa et al 2011 , Re F et al 2011a , 2011b . Enhancement of endocytosis by brain capillary endothelial tissue has also proven effective in delivering contrast agents across an intact BBB .
3.1.1.
Adsorptive-mediated transcytosis.
Adsorptivemediated transcytosis relies on the electrostatic interaction of a ligand with moieties expressed at the luminal surface of cerebral endothelial cells. Cell-penetrating peptides (e.g. TAT-derived peptides) and cationic proteins (e.g. albumin) are commonly used to enhance brain drug delivery via adsorptivemediated transcytosis (Bhaskar et al 2010) .
Receptor-mediated transcytosis.
Receptor-mediated transcytosis has been investigated more deeply. The discovery of receptors that are uniquely expressed by the CNS and are transcytosed across the BBB has opened new vistas to effective brain drug delivery. Receptor-mediated transcytosis has been demonstrated for a variety of proteins including growth factors, insulin, albumin, leptin, lactoferrin, iron binding protein p97 (melanotransferrin), transferrin and Angiopep-2 (Gabathuler 2010, p 2). Also, certain monoclonal antibodies (mAbs) directed against BBB receptors undergo receptormediated transcytosis. For instance, OX26 mAb binds to transferrin receptor (TfRs), avoiding competition with endogenous transferrin in the circulation because it binds to a different epitope of TfR. OX26 mAb is reportedly active to rats but not in mice or other species. Similar to OX26 mAb, 8D3 mAb and the R17217 mAb are also able to bind to transferrin receptors and can be transcytosed across the BBB. Depending on the species studied for brain-targeted delivery, appropriate mAbs will be used (van Rooy et al 2011) . For example, a fully humanized form of the mouse 83-14 anti-human insulin receptor mAb (i.e. humanized HIRMAb) may be considered in constructing a brain-targeted drug delivery if it is used in humans (Boado 2008) .
Imaging of brain lesions using nanotechnologies
Nanotechnology offers a new promise for imaging of brain lesions. This emerging technology may provide a platform for the combination of neurodiagnostic and nanoimaging. 
Neuroinflammation
Neuroinflammation represents a chronic, CNS specific response that is characterized by activated microglia at sites of neuronal injury. Neuroinflammation is a pathological hallmark of neurodegenerative diseases that may produce plaque formation, dystrophic neurite growth and excessive tau phosphorylation (Appel et al 2011) . Neuroinflammation is unique from inflammation in other organs, but does include some similar mechanisms such as the localized production of chemo-attractant molecules to the site of inflammation (Streit 2006 , Wood 2003 . Currently, the method of choice to image brain inflammation is the use of PET ligands like 11 C-PK11195 that bind to the peripheral benzodiazepine receptor recently renamed, Translocator Protein (TSPO). This target is poorly expressed in normal brain parenchyma, but its level rises during brain inflammation, injury or degeneration thanks to the increased activation of microglia. TSPO receptors are localized on the mitochondrial membrane of activated microglia/macrophage cells whose presence may be visualized using PET and selected ligands. Cluster of brain inflammation has been detected in preclinical models and patients with inflammatory, neurodegenerative and infectious diseases. However, using this technique it is not possible to distinguish resident microglial cells from activated macrophage deriving from periphery.
Targeting activated leukocytes infiltration.
Monocyte/macrophage infiltration in the CNS plays a key role in neuroinflammation , as well as in lesion development and brain injury in neurological diseases such as multiple sclerosis (MS) and stroke , Price et al 2003 , Stoll et al 1998 . As previously stated, the use of PET and radiopharmaceuticals that specifically target the mitochondrial translocator protein TSPO like 11 C-PK11195 has permitted imaging of different degenerative, inflammatory or infective diseases
of the brain but not distinguishing of inflammatory infiltration from resident cells (de Vries et al 2006). Knowledge of active phases of cell infiltration during CNS disorders is important because anti-inflammatory treatments can target cell adhesion molecules and chemokines guiding cellular trafficking.
Whereas histological analysis after biopsy gives a precise but static picture on the actual extent of inflammation within a relatively small lesion area, MRI allows follow-up of lesion development in time and space. Most studies have used SPIO/USPIO to visualize macrophages in the CNS. Several reports suggest that NP uptake by circulating monocytes and their migration towards inflammatory areas is the most important mechanism for cellular infiltration into the brain parenchyma. This process is a timely restricted event in experimental and clinical CNS disorders which is often unrelated to breakdown of the BBB. As for example; USPIO, administered intravenously in vivo and using MRI, have been shown to detect activated macrophage infiltration in MS either in the CNS of humans or rodent model (Dousset et al 1999a , 1999b , Floris et al 2004 , Rausch et al 2003 , in stroke either in human (Nighoghossian et al 2007 or animal brain ischemia (Kleinschnitz et al 2005 , Rausch et al 2001 , Rausch et al 2002 , in human or murine intracranial tumors (Neuwelt et al 2004 , Zimmer et al 1995 , in EAE (Baeten et al 2008 , Oude Engberink et al 2010 and in an ischemia/reperfusion long-lived rat model (Sekeljic et al 2011) .
The same issue has been investigated during an inflammatory response in mice after middle cerebral artery occlusion by Stroh et al (2006) , who used spleen-derived monocytes labelled ex vivo with USPIO and successively transfused into splenectomized animals. The authors showed that USPIO-labelled monocytes were engrafted at the lesion border zone in the brain. Beyond understanding of mechanism of BBB crossing by USPIO, the use of SPIO-labelled monocytes (Metz et al 2004) provides a better tool to specifically assess the time window of monocyte infiltration (Oude Engberink et al 2008) .
It should be pointed out that USPIO could be useful not only to study cell infiltration during CNS disorders, but also to detect BBB-disrupted brain regions: Oude Engberink et al (2010) detected USPIO infiltration by MRI, in the brain of EAE animal models in the period 1-6 h after NP administration, colocalized with a leaky BBB as revealed by histological analysis .
Altogether these investigations suggest USPIO as marker for both cellular infiltration and BBB damage.
A new class of very small USPIO has been developed as novel contrast medium in murine adoptive-transfer EAE. These NPs showed a higher sensitivity in detecting BBB alterations compared with Gd-enhanced MRI, providing complementary information of macrophage/microglia activity in inflammatory plaques that has not been visualized by conventional means (Tysiak et al 2009) . Clinical applications of such NPs are not yet available.
Targeting endothelial adhesion molecules expression in vascular inflammation.
Early inflammation of the CNS is associated with enhanced expression of cell adhesion molecules on brain endothelial cells, which mediate cellular infiltration; an alternative approach to detect inflamed areas of the brain is based on the targeting of these molecules. Attractive molecular imaging targets are the E-selectin (CD62E), endothelial leukocyte adhesion molecule, P-selectin, endothelial vascular and intercellular cell adhesion molecule-1 (VCAM-1; CD106; ICAM-1) (Carlos et al 1990) and the ligand, α4β1 integrin or VLA-4 (Elices et al 1990) . In a traumatic brain injury model, in vivo imaging of the expression of another cell adhesion molecule, E-selectin, was reported using a targeted USPIO contrast agent (Chapon et al 2009) . Jin et al (2009) have hypothesized the use of MR imaging with a P-selectin-binding USPIO contrast agent, MNP-PBP (magnetic nanoparticle-P-selectin binding peptide), to detect early neuroinflammatory response in acute ischemic stroke.
Brain ischemia and stroke
Cerebral ischemia evokes an inflammatory response similar to autoimmune disorders of the CNS, which contributes to lesion development and brain injury and, successively, tissue remodeling. Kim et al (2008) used SPIO-particles to determine whether the accumulation of macrophages could be seen in vivo in a reperfusion animal model of focal cerebral ischemia, induced by transient occlusion of the middle cerebral artery. At days 3 and 4 post-reperfusion, focal areas of signal loss indicating local accumulation of SPIO particles appeared in a part of the damaged brain. Areas of signal loss corresponded to local accumulation of iron-laden macrophages in histological sections, and SPIO-induced signal loss indicated active macrophage transmigration into the re-perfused brain.
In clinical stroke studies, Saleh et al (2007) determined the extent of USPIO enhancement on patients with typical clinical signs during early stages of ischemic stroke. USPIOdependent signal changes were spatially heterogeneous, reflecting the variable extent and distribution of macrophage infiltration into stroke lesions and concluded that USPIOenhanced MRI may help to more specifically target antiinflammatory therapy in patients with stroke. The same author in a previous (Saleh et al 2004, p 11 ) clinical phase II study tested the potential of USPIO-enhanced MRI for macrophage imaging in human ischemic stroke lesions. Two distinct components of USPIO-related signal changes were discernible, one associated with blood vessels, most likely reflecting a transient blood pool effect of the contrast agent, and one representing parenchymal enhancement matched with the expected distribution of macrophages. USPIO-induced signal alterations were independent of breakdown of the BBB.
Molecular imaging of brain tumours
Nanotechnology is expected to have a significant impact on the future diagnosis of brain tumors (Mohs and Provenzale 2010) and significant efforts have already been made (Ghaghada et al 2010) . In the past decade, numerous advances in the understanding of brain tumor physiology, tumor imaging and tumor therapy have been attained. Specifically, NPs have the potential to revolutionize brain tumor imaging as well as surgical and adjuvant treatments. In some cases, advances have resulted from refinements of pre-existing technologies (e.g. improvements of contrast-enhanced MRI). Gliomas are the most common and mortiferous type of primary brain tumors (Wrensch et al 2002) . The differentiation of central gliomas from normal brain parenchyma is crucial for an accurate resection of all diseased tissues. The effectiveness of tumor resection is severely limited by the poor visual contrast between gliomas and normal brain tissue by Gd chelateenhanced MRI .
Magnetic, iron based, NPs offer a potential method for tumor diagnosis with benefits that extend beyond the enhanced permeability and retention (EPR) effect (Greish 2007) . Chertok et al (2008) examined the applicability of magnetic iron oxide NPs for both magnetically enhanced brain tumor accumulation and non-invasive MRI monitoring. Rats' intravenous administration, along with magnetic targeting resulted in a 5-fold increase in the total glioma exposure to magnetic NPs over non-targeted tumors and a 3.6-fold enhancement in the TSI of NPs accumulation in glioma tissue over normal brain parenchyma. The same magnetic NPs have already been reported by Lübbe et al (1996) to be non-toxic and well tolerated in both preclinical and clinical trials after systemic administration. The preferential accumulation of SPIOs within gliomas and subsequent MRI contrast enhancement have also been demonstrated in vivo in tumors of a xenograft mouse model by Sun et al (2008) and also obtained by Veiseh et al (2009) .
SPIOs were also used with research purposes to assay the tropism capacity of mesenchymal stem cells (MSCs) to gliomas, to delineate the pattern of MSCs distribution in gliomas after systemic injection, using magnetic resonance imaging (Wu et al 2008) .
One of the hallmarks of gliomas is the regional occurrence of prominent angiogenesis which makes them candidates for antiangiogenic therapy. One complication of evaluating the effects of therapy is that antiangiogenic compounds may close the BBB and preclude extravasation of contrast agents. Claes et al (2008) show that regions of tumors that are treated with antiangiogenic therapy and may be missed by conventional Gd-DTPA-enhanced MR imaging are readily visualized using USPIO via blood pool contrast-enhanced imaging in mice. Also Christoforidis et al (2009) showed that USPIO administration significantly enhanced visualization of tumor microvascularity on gradient echo 8 T MRI and significantly improved visualization of tumor microvascularity in rats. The study of Beaumont et al (2009) shows that an iron-based BVf/VSI MRI experiment and a Gd-based DCE MRI experiment can be combined into a unique MRI protocol, provided that USPIO does not extravasate with the time frame of the DCE MRI experiment, for evaluating antiangiogenic therapies.
The enhanced angiogenesis in gliomas has been also approached by PET imaging using liposomes functionalized with PEG and enhancing their accumulation by passive targeting combined with Ala-Pro-Arg-Pro-Gly peptide functionalization, to home into angiogenic sites (Oku et al 2011, p 8) . Even a 1 mm diameter tumor could be imaged into rats bearing a glioma-type brain tumor by such liposomes, loaded with 1-[
18 F]fluoro-3,6-dioxatetracosane of brain tumors.
It is relevant to point out that new NPs are continuously developed. Sarin et al (2008 Sarin et al ( , 2009 showed that the intravenously administration of polyamidoamine dendrimers functionalized with magnetic resonance and fluorescence imaging probes were able to traverse pores of the blood-brain tumor barrier of rodents with malignant gliomas if they are smaller than 12 nm in diameter and possess long blood halflives. Shin et al (2009) have reported the potential utility of hollow manganese oxide NPs as as a dual contrast agent for simultaneous MRI imaging and drug delivery. Xie et al (2011) explored the lactoferrin-conjugated SPIO NPs as an MRI contrast agent for the detection of brain C6 gliomas in vivo in rats: these NPs provided a better picture or more sensitivity to represent brain glioma on MR images than that of SPIO. Chou et al (2010) synthesized water-soluble iron-platinum NPs as a dual modality biocompatible contrast agent for CT/MRI molecular imaging tested in tumor bearing animal after tail vein injection. Finally, a kit for the labelling with Technetium-99m (Tc) of AuNPs, conjugated to Lysbombesin, a cyclix peptide or thiol-mannose was developed to produce receptor-specific multimeric systems for in vivo SPET imaging. Results of the studies indicate that this agent is promising for molecular imaging of tumours and sentinel lymph node detection (Ocampo-García et al 2011).
Alzheimer's disease
AD is one of the most common age-related neurodegenerative diseases.
The pathogenesis of AD is highly complex (Khairallah and Kassem 2011) , but beta-amyloid deposition plays a central role, causing severe damage to neurons via a cascade of several downstream effects. This hypothesis has, however, not yet been directly tested in human beings because of the very limited possibility of imaging amyloid deposition in vivo (Hasan and Mooney 2011) . Early diagnosis of AD, before the onset of marked clinical symptoms, is thus critical in preventing the irreversible neuronal damage that eventually leads to dementia and ultimately death. Moreover, the visualization of amyloid plaques in the brain is important to monitor AD progression and to evaluate the efficacy of therapeutic interventions. As previously reported PET and radiopharmaceuticals like PIB allow the in vivo imaging of amyloid plaques also in the pre-symptomatic stage of AD. However, to avoid the use of radiation, several efforts are currently focused on the development of NPs for amyloids. NPs able to bind with high affinity the Aβ peptide in different aggregation forms are already tested in vitro (Canovi et al 2011 , Gobbi et al 2010 and in vivo . Using this approach the authors were able to differentiate AD transgenic mice from wild-type mice.
In order to develop efficient in vivo probes, polymeric n-butyl-2-cyanoacrylate (PBCA) NPs have been prepared and encapsulated with the radio-labelled amyloid affinity drug 125 I-CQ (CQ, 5-chloro-7-iodo-8-hydroxyquinoline) to improve its transport to brain and amyloid plaque retention. 125 I-CQ discriminately binds to the AD post-mortem brain tissue homogenates versus control. The 125 I-CQ-PBCA NPs crossed the BBB in wild-type mouse, giving an increased brain uptake measured in terms of % ID/g i.e. injected dose compared with 125 I-CQ. Brain retention of 125 I-CQ-PBCA NPs was significantly increased in the AD transgenic mice (APP/PS1) and in mice injected with aggregated Aβ1-42 peptide versus age-matched wild type controls. This showed that radioiodinated CQ-PBCA NPs are a promising delivery vehicle for in vivo SPECT ( 123 I) or PET ( 124 I) amyloid imaging agent (Kulkarni et al 2010, p 8) . Despite the existence of efficient radio-labelled probe for PET imaging these agents have the possibility to demonstrate the potential use of NPs as carrier for amyloid agents.
Peripheral blood-originating macrophages are linked to the cerebrovascular pathology associated with AD. MRI was used to non-invasively study microvascular lesions in amyloid precursor protein transgenic mouse AD models by intravenous administration of SPIOs, which are taken up by macrophages through absorptive endocytosis, 24 h before image acquisition (Beckmann et al 2011) .
NPs-based imaging was also focused to enhance the power of MRI imaging versus cerebral amyloid angiopathy (CAA). NPs conjugated with antibody against fibrillar human amyloid-β42 were also tested in mice AD models, resulting as promising agents for the in vivo imaging of CAA (Poduslo et al 2011) .
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by loss of motor neurons in the spinal cord, brain stem and motor cortex which dramatically reduces life expectancy (Naganska and Matyja 2011). Machtoub et al (2011) use MRI for imaging intravenously injected USPIOs, cross-linked with antibodies anti-CD4, in an ALS rat experimental model. In vivo MRI revealed marked signal intensity enhancements in specific pathological regions of the ALS brain as compared with the wild type.
Recently, MRI has been utilized to follow the immune cells labelled by USPIOs within the brain of a rodent model of ALS. MRI of USPIO-labelled T-cells revealed CD4+ lymphocyte infiltration in the midbrain/interbrain region .
Gliosis
Gliosis is a proliferation of astrocytes in damaged areas of the CNS. synthesized SPIOs linked to a short DNA sequence complementary to the cerebral mRNA of glial fibrillar acidic protein (GFAP) found in glia and astrocytes to detect gliosis by MRI in living mice brains after having induced BBB leakage. The SPIO-GFAP probe, administered by eyedrop solution to the conjunctival sac, effectively reported gliosis associated with acute neurological disorders in living animals.
NPs' toxicity
While the passage of the brain vasculature by engineered NPs represents one of the main hopes for innovative strategies in neurology (Barbu et al 2009) , it is important to point out that the BBB represents the main mechanism of defense of the CNS against potentially neurotoxic molecules, NPs included. In vivo and clinical data evaluating their toxic effects on neural cells are still scarce, given that the application of NPs to the CNS is at a nascent stage.
In fact, some NPs, showing at the beginning promising features for their use in imaging diagnostics, successively demonstrated their toxicity when utilized in vivo. This is the case of quantum dots and carbon nanotubes, that repeatedly proved to be toxic in vivo (Win-Shwe and Fujimaki 2011), and for this reason, their future use in clinics will be likely limited to in vitro diagnostics. In vivo experiments showed that gold NPs also have some neurotoxicity by causing transient microglia activation and induction of TLR-2 promoter activity in transgenic mice (Hutter et al 2010) . For these reasons, the benefit-risk balance deriving from the entrance into the CNS, currently still unknown, should be carefully evaluated for engineered NPs intended for brain-specific drug delivery, and diagnostics. When assessing the possible neurotoxicity of engineered NPs, it should be pointed out that surface functionalization, often employed for targeted delivery, can significantly alter the biological response and induce neurotoxicity of otherwise safe particles, as reported by Rivet et al (2011) . Therefore, this aspect also needs to be taken into consideration. Moreover, it should also be stressed that toxicity may rise by NPs-induced TJ opening of the BBB endothelia. For instance, an in vitro study by Olivier et al (1999) showed that PBCA NPs alone induced a permeabilization of a BBB model, which was presumably attributed to the toxicity of the carrier. However, the in vivo data are yet to be obtained for further confirmation.
Concerning the NPs described within this review, reliable data on their safety are available only for liposomes and iron oxide NPs and for this reason, a growing body of clinical applications is expected for the next years to come from these nanodevices. Liposomes are known from the 1960s and are generally considered to be non-toxic because they are made from naturally occurring lipids (Buse et al 2010) . In the case of clinical iron oxide agents (e.g. USPIO), they are considered to pose a low health hazard to the CNS, causing no pathological cell or myelin change after delivery to normal rat brain , Mulddon et al 2005 .
Perspectives and conclusion
At the state-of-the-art, high resolution techniques but with low sensitivity, such as CT and MRI, are clinically utilized for diagnosis of neuropathologies, by imaging the structure, function/pharmacology of the brain. Technological advances made possible by complex biomedical equipment, and in particular PET and SPECT, resulted into the development of high sensitivity, low resolution molecular imaging.
In spite of significant advances in neuroimaging, important limitations still exist and new approaches are therefore necessary. As for example, to increase the sensitivity of the current techniques especially when applied to the CNS and to enhance the delivery to the brain of contrast agents that do not cross the BBB. Nanotechnology, in particular NPs, has the potential to provide considerable improvements to this field.
This review discussed the background of nanotechnology's use in imaging of the CNS, its current status, future potentials and limits. In the complex, significant progress has been reached in the applications of nanotechnology for neuroimaging, in particular with iron-oxide and gold NPs, for MRI and CT, respectively. More investigation will be necessary to allow the translation from preclinical to concrete clinical applications, keeping in mind that for a successful approach, all the aspects connected to the use of NPs (functionalization, targeting, imaging and toxicity) have to be further developed.
